Chemoradiotherapy Sequenced Radical Surgery for Colorectal Cancer With PALNM

Launched by QILU HOSPITAL OF SHANDONG UNIVERSITY · Nov 18, 2021

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment approach for patients with left-sided colon and rectal cancer who also have rare cancer spread to nearby para-aortic lymph nodes. These lymph nodes are located near the aorta, the main artery in the body. The trial aims to assess whether surgically removing these lymph nodes, combined with chemotherapy and radiation before surgery, is safe and effective in helping patients become cancer-free.

To participate in this trial, individuals must be between 18 and 75 years old, have a confirmed diagnosis of left-sided colon or rectal cancer, and show evidence of cancer spread to specific lymph nodes through imaging tests. They should be able to tolerate surgery and not have other severe health issues. Participants will undergo the treatment and will be closely monitored for safety and how well the treatment works. It’s important to note that this trial is not yet recruiting participants, so interested individuals will need to wait for the study to start.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • age at enrollment is ≥ 18 and ≤ 75 years
• • ECOG PS 0-1
• • histologically confirmed left-sided colon and rectal carcinoma
• • synchronous para-aortic lymph node metastases confirmed by PET-CT, and located below the level of renal veins and above the bifurcation of iliac artery
• • patients potential to receive surgery and achieve no evidence of disease (NED)
• • able to tolerate surgery
• • providing written informed consent
• Exclusion Criteria:
• • local invasion or distant metastasis other than para-aoritc lymph nodes
• • history of other malignant tumor
• • coupled with severe systematic diseases (recent myocardial infarction, cardiomyopathy, or acute pulmonary infection)
• • emergency surgery